These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17605096)

  • 1. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease.
    Kostis JB
    Cardiovasc Drugs Ther; 2007 Aug; 21(4):297-309. PubMed ID: 17605096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia.
    Cybulsky M; Cook S; Kontsevaya AV; Vasiljev M; Leon DA
    BMC Cardiovasc Disord; 2016 Jun; 16():122. PubMed ID: 27255373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural antioxidant compounds in risk factors for CVD.
    Kaliora AC; Dedoussis GV
    Pharmacol Res; 2007 Aug; 56(2):99-109. PubMed ID: 17572098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease.
    Ferdinand KC
    Curr Med Res Opin; 2005 Jul; 21(7):1091-7. PubMed ID: 16004678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk factors among high-risk individuals attending the general practice at king Abdulaziz University hospital: a cross-sectional study.
    Ghamri RA; Alzahrani NS; Alharthi AM; Gadah HJ; Badoghaish BG; Alzahrani AA
    BMC Cardiovasc Disord; 2019 Nov; 19(1):268. PubMed ID: 31775642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of cardiovascular events in Italian patients with early discontinuations of antihypertensive, lipid-lowering, and antidiabetic treatments.
    Corrao G; Zambon A; Parodi A; Merlino L; Mancia G
    Am J Hypertens; 2012 May; 25(5):549-55. PubMed ID: 22278212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence with treatment in newly treated middle-aged patients with essential hypertension.
    Perreault S; Lamarre D; Blais L; Dragomir A; Berbiche D; Lalonde L; Laurier C; St-Maurice F; Collin J
    Ann Pharmacother; 2005 Sep; 39(9):1401-8. PubMed ID: 16076920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study).
    Fedacko J; Pella D; Jarcuska P; Sabol F; Kmec J; Lopuchovsky T; Merkovska L; Jedlickova L; Janicko M; Sajty M
    Adv Ther; 2013 Jan; 30(1):60-70. PubMed ID: 23328937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level.
    Roccatagliata D; Avanzini F; Monesi L; Caimi V; Lauri D; Longoni P; Marchioli R; Tombesi M; Tognoni G; Roncaglioni MC;
    Vasc Health Risk Manag; 2006; 2(4):507-14. PubMed ID: 17323606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program).
    Hobbs FD; Gensini G; Mancini GB; Manolis AJ; Bauer B; Böhler S; Genest J; Feldman R; Harvey P; Jenssen TG; Metcalfe M; da Silva PM;
    Int J Cardiol; 2006 Jun; 110(2):242-50. PubMed ID: 16338012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
    Cowie MR
    Int J Clin Pract; 2005 Jul; 59(7):839-46. PubMed ID: 15963213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification.
    Schmittdiel JA; Uratsu CS; Karter AJ; Heisler M; Subramanian U; Mangione CM; Selby JV
    J Gen Intern Med; 2008 May; 23(5):588-94. PubMed ID: 18317847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adherence to antihypertensive and lipid-lowering medications: a problem of public health, not yet resolved].
    Grosso G; Raciti T; Marventano S; Romeo I; Mistretta A
    Ann Ig; 2011; 23(2):173-84. PubMed ID: 21770233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.